These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31591439)

  • 1. Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters.
    Yuan C; Liu Z; Yu Q; Wang X; Bian M; Yu Z; Yu J
    Sci Rep; 2019 Oct; 9(1):14356. PubMed ID: 31591439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
    Gao Y; Li S; Xu D; Chen S; Cai Y; Jiang W; Zhang X; Sun J; Wang K; Chang B; Wang F; Hong M
    Chin J Cancer; 2017 Jul; 36(1):61. PubMed ID: 28754154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
    Kim HM; Lee J; Koo JS
    BMC Cancer; 2017 Oct; 17(1):690. PubMed ID: 29041905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary tumor resection for initially staged IV breast cancer: An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival.
    Erol T; İmamoğlu NE; Aydin B; Taşkiran ZE; Esendağli G; Kösemehmetoğlu K; Baykal A
    Medicine (Baltimore); 2019 Aug; 98(33):e16773. PubMed ID: 31415379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of PD-L1 and PD-1 in stage T4 rectal cancer tissues and surrounding metastatic lymph nodes and correlation with prognosis.
    Wang Y; Lu H; Li M
    Cell Mol Biol (Noisy-le-grand); 2022 Aug; 68(8):74-78. PubMed ID: 36800834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.
    Eckel-Passow JE; Ho TH; Serie DJ; Cheville JC; Houston Thompson R; Costello BA; Dong H; Kwon ED; Leibovich BC; Parker AS
    Cancer Med; 2020 Feb; 9(3):1152-1160. PubMed ID: 31829518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.
    Ito S; Masuda T; Noda M; Hu Q; Shimizu D; Kuroda Y; Eguchi H; Tobo T; Utsunomiya T; Mimori K
    Oncology; 2020; 98(7):501-511. PubMed ID: 32380498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.
    Schneider S; Kadletz L; Wiebringhaus R; Kenner L; Selzer E; Füreder T; Rajky O; Berghoff AS; Preusser M; Heiduschka G
    Histopathology; 2018 Oct; 73(4):573-584. PubMed ID: 29742291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells.
    Tawfik O; Kimler BF; Karnik T; Shehata P
    Hum Pathol; 2018 Oct; 80():170-178. PubMed ID: 29936058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the Possible Association between PD-1 (Rs11568821, Rs2227981, Rs2227982) and PD-L1 (Rs4143815, Rs2890658) Polymorphisms and Susceptibility to Breast Cancer in a Sample of Southeast Iranian Women.
    Karami S; Sattarifard H; Kiumarsi M; Sarabandi S; Taheri M; Hashemi M; Bahari G; Ghavami S
    Asian Pac J Cancer Prev; 2020 Oct; 21(10):3115-3123. PubMed ID: 33112575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
    Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
    BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Heterogeneity in PD-L1 expression on infiltrating immune cells between the primary and metastatic breast cancers].
    Wang XR; Zhang NN; Lyu F; Wang HL; Liu YP
    Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):430-434. PubMed ID: 32392925
    [No Abstract]   [Full Text] [Related]  

  • 13. Frequency of Expression of PD-1 and PD-L1 In Head And Neck Squamous Cell Carcinoma And their Association With Nodal Metastasis: A Cross-Sectional Study.
    Malik IS; Asif M; Bashir N; Ara N; Rashid F; Din HU; Malik NS; Bashir A
    Asian Pac J Cancer Prev; 2022 Feb; 23(2):467-473. PubMed ID: 35225458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.
    Zhang M; Sun H; Zhao S; Wang Y; Pu H; Wang Y; Zhang Q
    Oncotarget; 2017 May; 8(19):31347-31354. PubMed ID: 28430626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma.
    Zhang X; Yin X; Zhang H; Sun G; Yang Y; Chen J; Zhu X; Zhao P; Zhao J; Liu J; Chen N; Wang J; Shen P; Zeng H
    BMC Cancer; 2019 Apr; 19(1):360. PubMed ID: 30992011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteration of the immune microenvironment in the axillary metastatic lymph nodes of luminal A breast cancer patients.
    Wu M; Wang S; Yuan K; Xiong B; Li Y; Lyu S
    World J Surg Oncol; 2024 Jun; 22(1):172. PubMed ID: 38937736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
    Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
    Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers.
    Rozenblit M; Huang R; Danziger N; Hegde P; Alexander B; Ramkissoon S; Blenman K; Ross JS; Rimm DL; Pusztai L
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33239417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
    Loi S; Giobbie-Hurder A; Gombos A; Bachelot T; Hui R; Curigliano G; Campone M; Biganzoli L; Bonnefoi H; Jerusalem G; Bartsch R; Rabaglio-Poretti M; Kammler R; Maibach R; Smyth MJ; Di Leo A; Colleoni M; Viale G; Regan MM; André F;
    Lancet Oncol; 2019 Mar; 20(3):371-382. PubMed ID: 30765258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.